Seattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.38), $0.12 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $77.1 million versus the consensus estimate of $77.97 million.

2015 Financial Outlook

Seattle Genetics anticipates that 2015 revenues from ADCETRIS net product sales in the U.S. and Canada will be slightly higher than previously anticipated, and are now expected to be in the range of $210 million to $220 million. The company also now anticipates that 2015 research and development expenses will be in the range of $275 million to $300 million, primarily due to the $25 million upfront payment under the recent collaboration with Unum Therapeutics.

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.